Codexis Q3 2022 revenue $34.5M, net loss $10.0M; reaffirms FY2022 guidance

CODEXIS, INC.

2022-Q3 EPS reported -$0.32 revenue$108,215,000

Total Q3 revenue $34.5M, down 6% YoY from $36.8M; net loss $10.0M ($0.15/share) vs net income $2.2M in Q3 2021.
Product revenue $28.0M, down 2%; excluding COVID drug (PAXLOVID) sales, product revenue up 53% to $15.1M.
Reiterated FY2022 guidance: total revenue $135-141M, product revenue $112-118M (incl ~$75M from Pfizer).
New CEO Dr. Stephen Dilly, COO Kevin Norrett, GC Margaret Fitzgerald appointed; Rahul Singhvi added to Board.
Cash and equivalents $108.7M; expects cash to fund operations through at least end of 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CODEXIS, INC. reported third quarter ended September 30, 2022 results: revenue $34.5 million, net income $(10.0) million, or $0.15 per share, EPS $0.15 per share. Guidance reaffirmed.

Period: third quarter ended September 30, 2022
Revenue: $34.5 million
Net income: $(10.0) million, or $0.15 per share
EPS: $0.15 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenues for the third quarter 2022 were $34.5 million

View on SEC.gov

Browse all earnings releases →

CODEXIS, INC. filing history →

Source: SEC EDGAR

accession 0001200375-22-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.